The development of trastuzumab revolutionized the treatment of HER2+ breast cancer by introducing a monoclonal antibody that specifically targeted breast cancer cells that overexpressed aberrant HER2 receptors. This evidence concerns the gene ERBB2 and breast carcinoma.